Tuoxin Pharmaceutical Group Co

Tuoxin Pharmaceutical Group Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Tuoxin Pharmaceutical Group Co (301089.SZ) as of Nov 22, 2026 is 101.41 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -94.32 % — a change of -207.51% (higher).

FCF Conversion

101.41 %

YoY

-207.51%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Tuoxin Pharmaceutical Group Co is 2025 101.41 % . FCF Conversion Rate (FCF/EBITDA) of Tuoxin Pharmaceutical Group Co was 2024 -94.32 % . It decreases by -207.51% higher compared to the previous year.

The Tuoxin Pharmaceutical Group Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
18.14 CNY
Jan 1, 2019
16.61 CNY
Jan 1, 2020
40.67 CNY
Jan 1, 2021
-82.99 CNY
Jan 1, 2022
42.06 CNY
Jan 1, 2023
-65.11 CNY
Jan 1, 2024
-94.32 CNY
Jan 1, 2025
101.41 CNY
The Tuoxin Pharmaceutical Group Co FCF Conversion history
YEARFCF ConversionYoY
101.41 %-207.51%
-94.32 %+44.87%
-65.11 %-254.80%
42.06 %-150.68%
-82.99 %-304.05%
40.67 %+144.88%
16.61 %-8.43%
18.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tuoxin Pharmaceutical Group Co Stock analysis

What does Tuoxin Pharmaceutical Group Co do? Tuoxin Pharmaceutical Group Co Ltd develops and sells chemical synthetic biological fermented nucleoside APIs and pharmaceutical intermediates. The company's main products include pyrimidine series, purine series, nucleotide series, nucleoside series, and other nucleoside (acid) products such as citicoline sodium, ribavirin, inosine, acyclovir, azvudine, cytosine, 5-fluorocytosine, cytidine, and uridine. These products serve the virus, anti-tumor, and nervous system drug markets. Tuoxin primarily sells its products domestically and internationally, targeting pharmaceutical companies that manufacture antiviral, anticancer, and neurological medications. The firm's revenue comes from the sale of these raw materials and intermediates to both domestic and overseas pharmaceutical manufacturers. The company focuses on nucleoside (acid) products for pharmaceutical applications, with key offerings like citicoline sodium and ribavirin used in antiviral treatments. Its product portfolio includes acyclovir for viral infections and azvudine for HIV treatment, alongside intermediates such as cytosine and uridine. Tuoxin's sales are directed toward pharmaceutical manufacturers in China and abroad, who incorporate these materials into their drug production processes. The firm's business model relies on supplying essential raw materials to the global pharmaceutical industry for the production of antiviral, anticancer, and neurological drugs. Tuoxin Pharmaceutical Group's revenue streams are derived from the production and sale of nucleoside-based APIs and intermediates. The company's primary customers are pharmaceutical manufacturers that require these materials for developing virus, anti-tumor, and nervous system drugs. The products are distributed across domestic and international markets, with the firm maintaining a focus on chemical synthetic biological fermented nucleoside products. The business model emphasizes direct sales of raw materials and intermediates to manufacturers rather than consumer-facing products. Tuoxin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tuoxin Pharmaceutical Group Co stock

FCF Conversion Rate (FCF/EBITDA) of Tuoxin Pharmaceutical Group Co is 101.41 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Tuoxin Pharmaceutical Group Co changed from -94.32 % to 101.41 %, representing a -207.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Tuoxin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Tuoxin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tuoxin Pharmaceutical Group Co

All Key Metrics — Tuoxin Pharmaceutical Group Co